Think Almac...Solid form screening

Grant awarded to support the expansion of Almac’s small molecule API manufacturing plant

Your integrated API and analytical services provider

Tonmya™ is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by positive results from two Phase 3 studies

New Drug Application (NDA) submission to the FDA planned for second half of 2024

Tailor-made Pharmaceutical Development & Commercial Solutions

The Almac Group has today announced the completion of two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland meeting client demand in commercial manufacturing and packaging as well as peptide production.

By Dr Colin Lorimer, Formulation Development Manager, Almac Pharma Services

The new custom-built facility will consolidate the existing warehouses to support all manufacturing and laboratory activities.

With more than 50 years’ experience, we offer a wide range of specialised packaging solutions to meet, and deliver your product launch and ongoing commercial needs.

Almac Sciences’ Technology Group was selected as the winner of the “Life Sciences Team of the Year” category  during this year’s Irish Life Sciences Awards ceremony, held on 6 July 2023 at Crowne Plaza Hotel, Dublin..

Balancing speed with precision, our flexible suite of offerings provides you with a reliable, effective, and expert approach to support the successful and timely introduction and launch of your new product and market penetration into new territories.

Strengthened collaboration with University College Dublin (UCD) that will focus on the development of novel continuous flow protocols for accessing new industrially relevant drug targets.

Our product development service spans early to late phase clinical programs, offering technical experience and dedicated project management, and a track record of on-time delivery from state-of-the-art facilities.

Overall recognition received for compatibility, expertise, quality and reliability.

Non-GMP & GMP stable & radiolabelling expertise14C labelling of drug substance for human AME studies
Stable & radiolabelled metabolite synthesis
Specialist expertise in peptide & bioconjugate 14C labelling
QC, Analytical & QA integration
MHRA regulatory approved for 14C GMP manufactureof drug substance

Health Products Regulatory Authority (HPRA) has certified Almac Sciences Ireland (ASI) facility for testing of biologics after a successful audit

Over 30 years’ experience in peptide manufactureRapid throughput, high quality manufacture
Customised supply plan for your project needs
Free consultation on peptide design & manufacturability
Smooth transition to scale-up & cGMP manufacture
Strong emphasis on project management & customercare throughout project lifetime

Expanded GMP manufacturing facility now operational for use in clinical and / or commercial manufacturing

As a world leader in pharmaceutical services, Almac delivers early formulation development workprograms for DRF/PK/tox studies. Designed to maximise solubility and bioavailability withoutcompromising on chemical stability, the studies accelerate drug development to the clinic and minimizerisk in any downstream activities. Almac offer bespoke work packages specifically tailored to thephysiochemical properties of the API (BCS class II, III, or IV) for solubility or permeability enhancement.

As a world leader in pharmaceutical services, Almac deliversbespoke crystallisation development work programs for smallmolecules and peptides designed to provide a robust, scaleable,and transferrable crystallisation procedure to help accelerateclinical development and minimise risk in any downstreamactivities by eliminating batch-to-batch variability